A clinical trial (NCT07543679) evaluating ADHELASKIN technology by Tactinnov and École Centrale de Lyon for objective assessment of skin damage in patients with systemic sclerosis has been registered on ClinicalTrials.gov. The trial addresses limitations of the modified Rodnan skin score (mRSS), including inter- and intra-observer variability and limited sensitivity to subtle changes. ADHELASKIN uses an indentation method with ruby-based measurement to quantify rigidity, firmness, and elasticity of skin with improved accuracy. The study will classify patients as diffuse cutaneous or limited cutaneous SSc based on skin fibrosis extent.
